Phase I Trial of ZIO-101 in Patients With Solid Tumors
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
1. To determine the toxicities and maximum tolerated dose (MTD) of ZIO-101 when
administered intravenously once a day for 5 consecutive days every 4 weeks in subjects
with advanced solid tumors.
2. To determine the pharmacokinetic profile of ZIO-101 when administered intravenously once
a day for 5 consecutive days every 4 weeks.
Secondary Objective:
1. To determine the anti-tumor effects of ZIO-101.